Paul Richardson, MD

Director of Clinical Research, Jerome Lipper Multiple Myeloma Center
Clinical Program Leader, Dana Farber Cancer Institute
RJ Corman Professor of Medicine, Harvard Medical School
Boston, MA

After completing certifications in Internal Medicine, Hematology, and Medical Oncology, Dr. Paul Richardson joined the Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute in 1999 and became Clinical Director in 2001, where he has played a pivotal role in advancing multiple myeloma treatment. He helped develop several landmark therapies, including bortezomib, lenalidomide, pomalidomide, panobinostat, ixazomib, and breakthrough immunotherapies such as elotuzumab, daratumumab, and isatuximab, while also contributing to the development of belantamab mafodotin, melflufen, selinexor, and novel CELMoDs for relapsed and refractory myeloma. Over the past decade, he has led the development and global adoption of the lenalidomide, bortezomib, and dexamethasone (RVD) regimen, including its integration into the influential IFM/DFCI clinical trials for newly diagnosed patients, with findings published in the New England Journal of Medicine and presented at ASCO. Dr. Richardson has authored more than 800 publications, held numerous leadership roles in organizations such as the Multiple Myeloma Research Consortium, ASCO, and the Alliance Myeloma Committee, and has received multiple prestigious awards recognizing his contributions to clinical research and patient care, including the Warren Alpert Foundation Prize, the ASH Ernest Beutler Prize, the IMF Robert A. Kyle Lifetime Achievement Award, and the Giants of Cancer Care Award.